Physician Resources for Hematologic Malignancies

We collaborate with referring providers to ensure that more patients can access the most advanced care and treatment available. Through partnering with you, we can help your patients receive their care closer to home, reducing the time and cost of care without sacrificing quality.

Why Choose Us

Specialized Treatment for Blood Cancers and Related Disorders

The Hematologic Oncology Treatment Center at Dana-Farber Brigham Cancer Center provides highly specialized care for patients with all types of blood cancers, including:

Our team also leads clinical and research efforts focused on rare hematologic conditions:

The center includes our Stem Cell Transplantation and Cellular Therapies programs – both among the largest and most experienced in the world.

View all specialized centers and programs

Access to Clinical Trials

More than 100 innovative clinical trials are currently underway in the Center for Hematologic Oncology – offering new avenues of treatment for upfront and recurrent disease. The combined resources of our partner organizations within Dana-Farber/Harvard Cancer Center make us the largest cancer research center in the nation.

Search current hematologic cancer and blood disorders clinical trials, or call our disease-specific blood cancer specialists at 617-632-6246.

Patient Referrals and Consults

Complete our patient referral form, call 877-441-3324, or contact our disease centers directly. For urgent new-patient referrals, we offer immediate access to disease-specific blood cancer specialists: 

Use our directory to find specific contact information for physicians, nursing, and administrative staff.

Ongoing communication and collaboration with our referring partners are among our top priorities. We will keep you informed and connected in the shared care of your patients. Our physician portal, Physician Gateway, helps you keep track of patients you have referred to Dana-Farber Brigham Cancer Center for care.

Clinical Education Opportunities

We offer observerships for physicians to shadow clinicians in the Hematologic Malignancies, Stem Cell Transplantation, and Cellular Therapies programs. Observerships offer an opportunity to interact with our experts, shadow in outpatient clinics and other areas as approved by your sponsor, and participate in lab-based research. 

  • Observership curricula and scheduling are managed by each department.
  • Interested candidates must have an identified attending physician sponsor. Interested candidates should contact a member of our Hematologic Malignancies, Stem Cell Transplantation, or Cellular Therapies program to inquire about sponsorship.
  • Observership periods are two to four weeks in duration.
  • We offer observerships in our outpatient clinics only; there is no access to our inpatient hospital.
  • Application requirements:
    • CV, letter from home institution, observership fee.
    • Participants must meet our health requirements, which include proof of certain immunizations.

Email with questions about an observership with our Hematologic Malignancies, Stem Cell Transplantation, or Cellular Therapies program.

Subscribe to Advances in Hematologic Malignancies

This free biannual e-newsletter provides updates about Dana-Farber’s hematologic oncology research and care, current clinical trials, and upcoming CME programs.


Accreditations and Industry Leadership

Our clinicians hold presidency and leadership roles in national organizations, provide editorial oversight of influential journals, and are teachers in the field. Some of our affiliations and accreditations include:

    • Foundation for the Accreditation of Cellular Therapy (FACT), for stem cell transplant and immune effector cell therapies
    • U.S. Food and Drug Administration
    • American Association of Blood Banks (AABB)
    • Centers for Medicare and Medicaid Services
    • The Joint Commission
    • NMDP
    • Key member of the Alliance for Clinical Trials in Oncology's Multiple Myeloma Committee
    • Founding institution of the Multiple Myeloma Research Consortium (MMRC)
    • Member of the Center for International Blood and Marrow Transplant Research (CIBMTR), serving on working committees and the Executive Committee
    • Member of the Alliance for Clinical Trials in Oncology (formerly CALGB)
    • Charter Member of the Blood and Marrow Transplant Clinical Trials Network of the National Institutes of Health (BMT-CTN)
    • Accredited by the Center for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvement Amendment (CLIA)
    • Our HM/HSCT staff includes more than 45 physicians and 20 nurses, plus approximately 20 mid-level practitioners
    • Awarded Magnet® designation by American Nurses Credentialing Center
    • Disease Attacking the Immune System (DAISY) Foundation Award participant
    • Oncology Nursing Society Outstanding Employer Award participant
    • Teaching affiliate of Harvard Medical School
    • Member of Dana-Farber/Harvard Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center
    • Responsible for oversight of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines
    • Food and Drug Administration (FDA)-registered
    • Joint Commission Hospital accreditation
    • Joint Commission Laboratory accreditation
    • Staff leadership and participation in national organizations, including:
      • American Society for Transplantation and Cellular therapy (ASTCT)
      • American Society of Hematology (ASH)
      • Lymphoma Research Foundation (LRF) Scientific Advisory Board
      • Board of Scientific Advisors of the National Cancer Institute (NCI)
      • National Marrow Donor Program
      • Center for International Blood and Marrow Transplant Research
      • International Myeloma Working Group